Eli Lilly and Co
Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs
The Trump administration is preparing to impose new tariffs on branded drugs from pharmaceutical companies that have not struck landmark deals with the president to lower their U.S. drug prices, CNBC has learned. Patented medications and their active ingredients would be hit with a 100% tariff, according to a draft of the document obtained by […]
Read More
Trump’s address, SpaceX IPO, Sam’s Club membership prices and more in Morning Squawk
This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Happy Thursday. It’s the one-year anniversary of President Donald Trump’s initial tariff unveiling, what the president dubbed “liberation day.” Stock futures are falling this morning. The three major indexes are coming off another winning day. Here are five key things investors need […]
Read More
Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison
Wegovy semaglutide tablets. Michael Siluk | Universal Images Group | Getty Images The Wegovy pill showed more pronounced weight loss and less cumbersome side effects than Eli Lilly‘s rival pill that was approved this week, Novo Nordisk said Thursday. Oral Wegovy demonstrated “significantly greater mean weight loss” than orforglipron, which Lilly will sell under the […]
Read More
Inside India newsletter: The worst might not be over for Indian equities
Hello, this is Priyanka Salve, writing to you from Singapore. Welcome to the latest edition of “Inside India“ — your one-stop destination for stories and developments from the world’s fastest growing large economy. Indian markets have been rattled by the Iran war, with foreign investors fleeing and valuations slipping to rare lows. But fund managers […]
Read More
Eli Lilly opposes push to pass Trump’s drug pricing deals into law, CEO says
David Ricks, CEO of Eli Lilly, speaks in the Oval Office during an event about weight-loss drugs at the White House in Washington, DC on Nov. 6, 2025. Andrew Caballero-Reynolds | AFP | Getty Images Eli Lilly opposes the White House’s push to codify “most favored nation” drug pricing into law, CEO Dave Ricks said […]
Read More
Stocks making the biggest moves midday: Eli Lilly, Hasbro, Philip Morris, Intel, Micron & more
Check out the companies making the biggest moves in midday trading: Eli Lilly — The Food and Drug Administration approved Foundayo , the company’s once-a-day GLP-1 pill to treat obesity. Shares rose about 4% on the news. Hasbro — The toymaker fell more than 4% after it disclosed a cybersecurity incident where there was unauthorized […]
Read More
FDA approves Eli Lilly’s GLP-1 pill, opening the next phase of the weight loss drug market
The U.S. Food and Drug Administration approved Eli Lilly‘s GLP-1 pill, the company said, a major milestone for the Indianapolis-based drugmaker and one that will test the market for new weight-loss medications. Lilly said the once-daily pill, Foundayo, will start shipping from direct-to-consumer platform LillyDirect on Monday and will be available at pharmacies and on […]
Read More
Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs
Eli Lilly Chair and CEO Dave Ricks speaks during a press conference in Houston, Texas, Sept. 23, 2025. Antranik Tavitian | Reuters Eli Lilly has agreed to pay up to $7.8 billion to acquire Centessa Pharmaceuticals and its experimental drug for excessive daytime sleepiness, the company said Tuesday. Centessa is one of several companies working […]
Read More
Wall Street’s rough month, Powell’s inflation outlook, GLP-1 subscription and more in Morning Squawk
This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Happy Tuesday. In a partnership you might not have seen coming, Warren Buffett is teaming up with the NBA’s Stephen Curry to revive his iconic charity lunch. Stock futures are rising this morning. The S&P 500 ended yesterday’s session within striking distance […]
Read More
Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly
Wegovy semaglutide tablets. Michael Siluk | Universal Images Group | Getty Images Novo Nordisk on Tuesday launched a multi-month subscription program for its Wegovy obesity drug products that aims to ensure cash-paying patients see lower, “predictable” monthly prices. Eligible patients can choose between three-, six- or 12-month subscriptions for the Wegovy injection or the two […]
Read More